首页 > 最新文献

Transfusion Medicine最新文献

英文 中文
Extracellular vesicles in ageing cold-stored whole blood may not compensate for the decreasing haemostatic function in vitro. 老化的冷藏全血中的细胞外囊泡可能无法弥补体外止血功能的下降。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-06-01 Epub Date: 2025-01-24 DOI: 10.1111/tme.13122
Petra Ilvonen, Sanna Susila, Ulla Impola, Reetta Pusa, Tuukka Helin, Lotta Joutsi-Korhonen, Saara Laitinen, Jouni Lauronen, Minna Ilmakunnas

Background: Extracellular vesicles (EVs) have procoagulative properties. As EVs are known to accumulate in stored blood products, we compared the EV content and coagulation capacity of leukoreduced cold-stored whole blood (CSWB) with current prehospital and in-hospital component therapies to understand the role of EVs in the haemostatic capacity of ageing CSWB.

Materials and methods: Blood was obtained from 12 O RhD-positive male donors. CSWB was compared with in-hospital component therapy of red blood cells (RBCs), OctaplasLG and buffy-coat platelets and prehospital component therapy of RBC and lyophilized plasma. Samples were drawn on Days 1 and 14 of CSWB and RBC cold storage. Blood count, haemolysis markers, rotational thromboelastometry, sonorheometry and thrombin generation were analysed. EVs were analysed using nanoparticle tracking analysis and cellular origin was determined using imaging flow cytometry.

Results: There was a trend towards increased production of both platelet and RBC-derived EVs during CSWB storage. Particle count increased during storage, whereas thrombin generation slowed down and in viscoelastic assays, clotting times prolonged, clot formation became impaired, and stiffness of the resulting clot decreased.

Conclusion: Both platelet and RBC-derived EVs increased in number in CSWB during storage. This did not appear to compensate for the in vitro decreasing haemostatic capacity of ageing CSWB, suggesting EVs produced during storage may not have active procoagulative effects, but rather reflect the ageing of blood cells.

背景:细胞外囊泡(EVs)具有促凝特性。由于已知EV会在储存的血液制品中积累,我们将白细胞诱导的冷藏全血(CSWB)的EV含量和凝血能力与目前的院前和院内成分疗法进行比较,以了解EV在老化的CSWB的止血能力中的作用。材料和方法:血液采集自12例rh阳性男性献血者。将CSWB与院内红细胞(RBC)、八层血小板(OctaplasLG)和褐皮血小板(buffucoat血小板)成分治疗和院前红细胞(RBC)和冻干血浆成分治疗进行比较。分别于第1天和第14天抽取CSWB和RBC冷库样品。分析了血细胞计数、溶血标志物、旋转血栓弹性测量、超声测量和凝血酶生成。采用纳米颗粒跟踪分析分析ev,采用成像流式细胞术确定细胞来源。结果:在CSWB储存期间,血小板和红细胞来源的ev均有增加的趋势。颗粒计数在储存过程中增加,而凝血酶的产生减慢,在粘弹性试验中,凝血时间延长,凝块形成受损,凝块的硬度降低。结论:CSWB中血小板和红细胞源性EVs数量均增加。这似乎并不能弥补衰老CSWB在体外降低的止血能力,这表明在储存过程中产生的ev可能没有积极的促凝作用,而是反映了血细胞的老化。
{"title":"Extracellular vesicles in ageing cold-stored whole blood may not compensate for the decreasing haemostatic function in vitro.","authors":"Petra Ilvonen, Sanna Susila, Ulla Impola, Reetta Pusa, Tuukka Helin, Lotta Joutsi-Korhonen, Saara Laitinen, Jouni Lauronen, Minna Ilmakunnas","doi":"10.1111/tme.13122","DOIUrl":"10.1111/tme.13122","url":null,"abstract":"<p><strong>Background: </strong>Extracellular vesicles (EVs) have procoagulative properties. As EVs are known to accumulate in stored blood products, we compared the EV content and coagulation capacity of leukoreduced cold-stored whole blood (CSWB) with current prehospital and in-hospital component therapies to understand the role of EVs in the haemostatic capacity of ageing CSWB.</p><p><strong>Materials and methods: </strong>Blood was obtained from 12 O RhD-positive male donors. CSWB was compared with in-hospital component therapy of red blood cells (RBCs), OctaplasLG and buffy-coat platelets and prehospital component therapy of RBC and lyophilized plasma. Samples were drawn on Days 1 and 14 of CSWB and RBC cold storage. Blood count, haemolysis markers, rotational thromboelastometry, sonorheometry and thrombin generation were analysed. EVs were analysed using nanoparticle tracking analysis and cellular origin was determined using imaging flow cytometry.</p><p><strong>Results: </strong>There was a trend towards increased production of both platelet and RBC-derived EVs during CSWB storage. Particle count increased during storage, whereas thrombin generation slowed down and in viscoelastic assays, clotting times prolonged, clot formation became impaired, and stiffness of the resulting clot decreased.</p><p><strong>Conclusion: </strong>Both platelet and RBC-derived EVs increased in number in CSWB during storage. This did not appear to compensate for the in vitro decreasing haemostatic capacity of ageing CSWB, suggesting EVs produced during storage may not have active procoagulative effects, but rather reflect the ageing of blood cells.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"275-286"},"PeriodicalIF":1.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-Ce in haemolytic disease of the foetus and newborn. 抗- ce在胎儿和新生儿溶血性疾病中的应用。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-06-01 Epub Date: 2025-03-05 DOI: 10.1111/tme.13134
Rebecca O'Grady, Joan Fitzgerald, Jan Miletin, Carmen Regan, Fergus Guilfoyle, Edel Scally, Catherine Flynn

Objectives: To report a delayed case of severe haemolytic disease of the foetus and newborn (HDFN) due to Anti-Ce.

Background: HDFN due to maternal antibodies is potentially fatal. As a result, antibody levels and foetal anaemia are periodically monitored and risk assessed throughout pregnancy. HDFN due to Anti-Ce is rare.

Case report: A 29-year-old Caucasian female with low titre Anti-Ce and Anti-e antenatally delivered a term baby girl that required multiple transfusions and hospital admissions early in life. The apparent clinical severity of HDFN resulted in investigative testing of a maternal admission sample at delivery for titre levels. Anti-Ce was identified as the cause of HDFN in this case, following an eightfold increase in titre levels from week 28 gestation (titre = 4) to term (titre = 32).

Discussion: The severe HDFN outlined in this case was unexpected due to the antibody specificity and low titres antenatally. The Anti-Ce with a titre of 32 implicated in this study is on the threshold for specialist foetal team involvement and vigilant monitoring as per BSH guidelines.

Conclusion: Anti-Ce titre monitoring beyond 28 weeks gestation and specialist foetal team involvement early in pregnancy should be considered despite current BSH Guidelines, along with extended neonatal monitoring.

目的:报告一例因抗- ce引起的延迟性严重胎儿和新生儿溶血性疾病(hddn)。背景:由母体抗体引起的HDFN可能是致命的。因此,抗体水平和胎儿贫血在整个怀孕期间进行定期监测和风险评估。Anti-Ce引起的hdf是罕见的。病例报告:一名29岁的白人女性,抗- ce和抗-e低滴度,产前分娩了一名足月女婴,需要多次输血并在生命早期住院。hdf的明显临床严重程度导致在分娩时对产妇入院样本进行滴度水平的调查性检测。从妊娠28周(滴度= 4)到足月(滴度= 32),Anti-Ce被确定为hdf的原因。讨论:由于抗体特异性和产前低滴度,本病例中描述的严重HDFN是出乎意料的。根据BSH指南,本研究中涉及的Anti-Ce滴度为32,处于专家胎儿团队参与和警惕监测的阈值。结论:尽管目前的BSH指南,仍应考虑妊娠28周以上的抗- ce滴度监测和妊娠早期专家胎儿小组的参与,并延长新生儿监测。
{"title":"Anti-Ce in haemolytic disease of the foetus and newborn.","authors":"Rebecca O'Grady, Joan Fitzgerald, Jan Miletin, Carmen Regan, Fergus Guilfoyle, Edel Scally, Catherine Flynn","doi":"10.1111/tme.13134","DOIUrl":"10.1111/tme.13134","url":null,"abstract":"<p><strong>Objectives: </strong>To report a delayed case of severe haemolytic disease of the foetus and newborn (HDFN) due to Anti-Ce.</p><p><strong>Background: </strong>HDFN due to maternal antibodies is potentially fatal. As a result, antibody levels and foetal anaemia are periodically monitored and risk assessed throughout pregnancy. HDFN due to Anti-Ce is rare.</p><p><strong>Case report: </strong>A 29-year-old Caucasian female with low titre Anti-Ce and Anti-e antenatally delivered a term baby girl that required multiple transfusions and hospital admissions early in life. The apparent clinical severity of HDFN resulted in investigative testing of a maternal admission sample at delivery for titre levels. Anti-Ce was identified as the cause of HDFN in this case, following an eightfold increase in titre levels from week 28 gestation (titre = 4) to term (titre = 32).</p><p><strong>Discussion: </strong>The severe HDFN outlined in this case was unexpected due to the antibody specificity and low titres antenatally. The Anti-Ce with a titre of 32 implicated in this study is on the threshold for specialist foetal team involvement and vigilant monitoring as per BSH guidelines.</p><p><strong>Conclusion: </strong>Anti-Ce titre monitoring beyond 28 weeks gestation and specialist foetal team involvement early in pregnancy should be considered despite current BSH Guidelines, along with extended neonatal monitoring.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"287-290"},"PeriodicalIF":1.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143568342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of anaemia among blood donors in eastern Morocco: The need for pre-donation haemoglobin assessment. 摩洛哥东部献血者中贫血的流行:捐献前血红蛋白评估的必要性。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-06-01 Epub Date: 2025-02-13 DOI: 10.1111/tme.13133
Ihab Belmokhtar, Karam Yahya Belmokhtar, Saida Lhousni, Redouane Boulouiz, Zaina Sidqi, Mohammed Choukri, Rachid Seddik, Mohammed Bellaoui

Background: Anaemia remains the main cause of deferral in blood donation. However, in Morocco, pre-donation haemoglobin measurement is not systematic.

Objectives: The aim of this study was to determine the prevalence of anaemia and associated factors such as sex, age and iron deficiency among blood donors in eastern Morocco in order to improve donor management practices.

Methods/materials: The study involved 2013 blood donors from the BRO Biobank. Blood samples were analysed using an automatic blood cell analyser for complete blood counts. Serum ferritin was measured by chemical and immunological analyser. Anaemia was defined as haemoglobin levels less than 13 g/dL in men and 12 g/dL in women, according to the WHO recommendation.

Results: The overall prevalence of anaemia in eastern Morocco was 9.84% and it varied significantly by region. The majority of anaemic individuals were iron-deprived (88.64%). Anaemia was much higher in females (14.74%) than in males (5.46%). The highest prevalence of anaemia among females was in the age group of 18-20 years (25.2%), while among males it was in the age group of 61-65 years (18.52%).

Conclusions: The high prevalence of anaemia among blood donors in eastern Morocco highlights the need to implement pre-donation haemoglobin assessment in donor selection guidelines and to consider optional ferritin testing for at-risk populations. Moreover, educating donors about iron deficiency and iron-rich diets is essential for sustaining donor health and eligibility.

背景:贫血仍然是推迟献血的主要原因。然而,在摩洛哥,献血前的血红蛋白测量并不系统:本研究旨在确定摩洛哥东部献血者中贫血症的患病率及相关因素,如性别、年龄和缺铁情况,以改进献血者管理方法:这项研究涉及来自 BRO 生物库的 2013 名献血者。使用自动血细胞分析仪对血样进行全血细胞计数分析。使用化学和免疫分析仪测量血清铁蛋白。根据世界卫生组织的建议,贫血的定义是男性血红蛋白水平低于 13 g/dL,女性血红蛋白水平低于 12 g/dL:摩洛哥东部贫血症的总发病率为 9.84%,不同地区的发病率差异很大。大多数贫血者缺铁(88.64%)。女性贫血率(14.74%)远高于男性(5.46%)。女性贫血患病率最高的年龄段为 18-20 岁(25.2%),而男性贫血患病率最高的年龄段为 61-65 岁(18.52%):摩洛哥东部献血者中贫血症的高发率突出表明,有必要在献血者选择指南中实施献血前血红蛋白评估,并考虑对高危人群进行可选的铁蛋白检测。此外,对献血者进行有关缺铁和富含铁饮食的教育对于保持献血者的健康和献血资格至关重要。
{"title":"Prevalence of anaemia among blood donors in eastern Morocco: The need for pre-donation haemoglobin assessment.","authors":"Ihab Belmokhtar, Karam Yahya Belmokhtar, Saida Lhousni, Redouane Boulouiz, Zaina Sidqi, Mohammed Choukri, Rachid Seddik, Mohammed Bellaoui","doi":"10.1111/tme.13133","DOIUrl":"10.1111/tme.13133","url":null,"abstract":"<p><strong>Background: </strong>Anaemia remains the main cause of deferral in blood donation. However, in Morocco, pre-donation haemoglobin measurement is not systematic.</p><p><strong>Objectives: </strong>The aim of this study was to determine the prevalence of anaemia and associated factors such as sex, age and iron deficiency among blood donors in eastern Morocco in order to improve donor management practices.</p><p><strong>Methods/materials: </strong>The study involved 2013 blood donors from the BRO Biobank. Blood samples were analysed using an automatic blood cell analyser for complete blood counts. Serum ferritin was measured by chemical and immunological analyser. Anaemia was defined as haemoglobin levels less than 13 g/dL in men and 12 g/dL in women, according to the WHO recommendation.</p><p><strong>Results: </strong>The overall prevalence of anaemia in eastern Morocco was 9.84% and it varied significantly by region. The majority of anaemic individuals were iron-deprived (88.64%). Anaemia was much higher in females (14.74%) than in males (5.46%). The highest prevalence of anaemia among females was in the age group of 18-20 years (25.2%), while among males it was in the age group of 61-65 years (18.52%).</p><p><strong>Conclusions: </strong>The high prevalence of anaemia among blood donors in eastern Morocco highlights the need to implement pre-donation haemoglobin assessment in donor selection guidelines and to consider optional ferritin testing for at-risk populations. Moreover, educating donors about iron deficiency and iron-rich diets is essential for sustaining donor health and eligibility.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"243-249"},"PeriodicalIF":1.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antigen masking indirect antiglobulin test can mitigate the interference of Mezagitamab, a novel anti-CD38 antibody, in serological pre-transfusion testing. 抗原掩盖间接抗球蛋白试验可以减轻新型抗cd38抗体Mezagitamab对输血前血清学检测的干扰。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-04-09 DOI: 10.1111/tme.13139
Cora P Habicht, Clemens Schneeweiss

Objectives: Investigation of the interference of mezagitamab in serological pre-transfusion testing and the use of DaraEx to overcome it.

Background: Administration of anti-CD38 antibodies is a state-of-the-art therapy for patients diagnosed with multiple myeloma. However, treatment with the currently approved anti-CD38 antibodies regularly results in widespread agglutination of red blood cells in serological pre-transfusion testing, making the determination of irregular antibodies and timely transfusion of compatible blood a challenge. Mezagitamab, a novel monoclonal anti-CD38 antibody, is currently under clinical investigation, not only for the treatment of multiple myeloma but also for other indications such as generalised myasthenia gravis.

Methods/materials: Mezagitamab or daratumumab spiked plasmas, with or without irregular antibodies, were tested in column agglutination technique cards. DaraEx was used to mitigate occurring interferences.

Results: Mezagitamab interferes with the indirect antiglobulin test, with comparable titers but weaker reaction strengths than daratumumab. DaraEx, a reagent containing Fab fragments of an anti-CD38 antibody, is able to completely overcome this interference in the antigen masking indirect antiglobulin test (AMIAT). DaraEx treatment does not interfere with tested irregular antibodies.

Conclusion: All novel anti-CD38 antibodies, such as mezagitamab, have the potential to interfere in serological pre-transfusion testing. While masking only one epitope, DaraEx has so far been an effective mitigation for all clinical anti-CD38 antibodies.

目的:探讨美扎吉他单抗对输血前血清学检测的干扰及应用DaraEx克服干扰的方法。背景:抗cd38抗体是多发性骨髓瘤患者最先进的治疗方法。然而,使用目前批准的抗cd38抗体治疗通常会导致血清学输血前检测中广泛的红细胞凝集,这使得不规则抗体的确定和及时输血成为一个挑战。Mezagitamab是一种新型单克隆抗cd38抗体,目前正处于临床研究阶段,不仅可用于治疗多发性骨髓瘤,还可用于其他适应症,如全身性重症肌无力。方法/材料:Mezagitamab或daratumumab加标血浆,有或没有不规则抗体,在柱凝集技术卡上进行检测。DaraEx用于减轻发生的干扰。结果:Mezagitamab干扰间接抗球蛋白试验,其滴度相当,但反应强度弱于daratumumab。DaraEx是一种含有抗cd38抗体Fab片段的试剂,能够在抗原掩蔽间接抗球蛋白试验(AMIAT)中完全克服这种干扰。DaraEx治疗不会干扰检测的不规则抗体。结论:所有新型抗cd38抗体,如mezagitamab,都有可能干扰血清学输血前检测。虽然DaraEx仅屏蔽一个表位,但迄今为止,它已有效缓解了所有临床抗cd38抗体。
{"title":"Antigen masking indirect antiglobulin test can mitigate the interference of Mezagitamab, a novel anti-CD38 antibody, in serological pre-transfusion testing.","authors":"Cora P Habicht, Clemens Schneeweiss","doi":"10.1111/tme.13139","DOIUrl":"https://doi.org/10.1111/tme.13139","url":null,"abstract":"<p><strong>Objectives: </strong>Investigation of the interference of mezagitamab in serological pre-transfusion testing and the use of DaraEx to overcome it.</p><p><strong>Background: </strong>Administration of anti-CD38 antibodies is a state-of-the-art therapy for patients diagnosed with multiple myeloma. However, treatment with the currently approved anti-CD38 antibodies regularly results in widespread agglutination of red blood cells in serological pre-transfusion testing, making the determination of irregular antibodies and timely transfusion of compatible blood a challenge. Mezagitamab, a novel monoclonal anti-CD38 antibody, is currently under clinical investigation, not only for the treatment of multiple myeloma but also for other indications such as generalised myasthenia gravis.</p><p><strong>Methods/materials: </strong>Mezagitamab or daratumumab spiked plasmas, with or without irregular antibodies, were tested in column agglutination technique cards. DaraEx was used to mitigate occurring interferences.</p><p><strong>Results: </strong>Mezagitamab interferes with the indirect antiglobulin test, with comparable titers but weaker reaction strengths than daratumumab. DaraEx, a reagent containing Fab fragments of an anti-CD38 antibody, is able to completely overcome this interference in the antigen masking indirect antiglobulin test (AMIAT). DaraEx treatment does not interfere with tested irregular antibodies.</p><p><strong>Conclusion: </strong>All novel anti-CD38 antibodies, such as mezagitamab, have the potential to interfere in serological pre-transfusion testing. While masking only one epitope, DaraEx has so far been an effective mitigation for all clinical anti-CD38 antibodies.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding hepcidin for iron management in pregnancy. 了解hepcidin在妊娠期铁管理中的作用。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-04-01 Epub Date: 2025-01-28 DOI: 10.1111/tme.13125
Sarah Rosson, Sue Pavord

Iron deficiency anaemia (IDA) poses a significant health challenge during pregnancy, affecting up to 30% of pregnant women in the UK. It has been linked to poor health outcomes for the mother, foetus, and the infant. Despite its prevalence and impact, current diagnostic and therapeutic approaches are limited. Ensuring an adequate iron status in pregnancy requires prompt investigation and treatment whilst avoiding excessive iron supplementation and its associated side effects. Hepcidin, a key regulator of iron trafficking in the body, has emerged as a promising candidate for tailoring iron supplementation to individual needs and responsiveness. However, current research on hepcidin-based approaches yields mixed findings, necessitating a comprehensive review to elucidate its potential utility in guiding iron therapy for pregnant women with IDA. This literature review seeks to synthesise existing evidence to explore the role of hepcidin in personalised iron supplementation for pregnant women with IDA and to identify avenues for future research to pave the way for improved management of IDA in pregnancy.

缺铁性贫血(IDA)对怀孕期间的健康构成重大挑战,影响英国多达30%的孕妇。它与母亲、胎儿和婴儿的健康状况不佳有关。尽管其流行和影响,目前的诊断和治疗方法是有限的。确保怀孕期间铁含量充足,需要及时调查和治疗,同时避免过量补充铁及其相关副作用。Hepcidin是体内铁运输的关键调节因子,已成为一种有希望的候选药物,可以根据个人需求和反应性来调整铁的补充。然而,目前基于hepcidin的方法的研究结果好坏参半,需要进行全面的综述,以阐明其在指导IDA孕妇铁治疗方面的潜在效用。本文献综述旨在综合现有证据,探讨hepcidin在IDA孕妇个体化补铁中的作用,并为未来的研究确定途径,为改善妊娠期IDA的管理铺平道路。
{"title":"Understanding hepcidin for iron management in pregnancy.","authors":"Sarah Rosson, Sue Pavord","doi":"10.1111/tme.13125","DOIUrl":"10.1111/tme.13125","url":null,"abstract":"<p><p>Iron deficiency anaemia (IDA) poses a significant health challenge during pregnancy, affecting up to 30% of pregnant women in the UK. It has been linked to poor health outcomes for the mother, foetus, and the infant. Despite its prevalence and impact, current diagnostic and therapeutic approaches are limited. Ensuring an adequate iron status in pregnancy requires prompt investigation and treatment whilst avoiding excessive iron supplementation and its associated side effects. Hepcidin, a key regulator of iron trafficking in the body, has emerged as a promising candidate for tailoring iron supplementation to individual needs and responsiveness. However, current research on hepcidin-based approaches yields mixed findings, necessitating a comprehensive review to elucidate its potential utility in guiding iron therapy for pregnant women with IDA. This literature review seeks to synthesise existing evidence to explore the role of hepcidin in personalised iron supplementation for pregnant women with IDA and to identify avenues for future research to pave the way for improved management of IDA in pregnancy.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"109-115"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143053569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of Asian-Indian criteria for higher body mass index and preservative solutions on haemolysis of stored red blood cells: A prospective observational study. 亚洲-印度高体重指数标准和防腐剂溶液对储存红细胞溶血的影响:一项前瞻性观察研究。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-30 DOI: 10.1111/tme.13120
Somnath Mukherjee, Stephy Varghese K, Satya Prakash, Debasish Mishra, Ansuman Sahu

Introduction: The quality of packed red blood cells (PRBC) is influenced by various factors such as the collection and processing method, storage conditions, type of bag materials used, anticoagulant properties, and donor characteristics. Studies have indicated that haemolysis in stored RBC bags is linked to male sex, older age, high haemoglobin count, and increased body mass index (BMI). The study's primary objective was to investigate whether a high BMI, as per Asian Pacific criteria among donors, is associated with an elevated haemolysis rate in stored RBC. Additionally, the study aimed to examine any protective effects of different types of preservatives added to blood bags against RBC haemolysis during storage.

Methods: Stored RBCs from 100 blood donors with different BMI are analysed for haemolysis on 0, 21, and last day (35/42 days) of storage. A BMI cut-off of 23 was taken for healthy and overweight consideration in blood donors. The blood bags selected for storage were either with additive solution (SAGM) or without additive along with an anticoagulant. The association of the percentage of haemolysis with different variables like age, BMI, and Haemoglobin of the donor were analysed. The correlation between the haematocrit of the bag and haemolysis was determined.

Results: This study did not find any significant increase in the percentage of haemolysis in blood bags with higher BMI on the last day of storage (p = 0.424). The haemolysis percentage was higher in bags without SAGM than in bags with an additive solution (p = 0.000). The high haematocrit of the bag has a significant positive correlation with the percentage of haemolysis (p = 0.002). Significantly higher haemolysis in CPDA-1 bags of donor RBC units of BMI >23 groups was observed (p = 0.000) compared to those stored in CPD-SAGM bags.

Conclusion: Indian population for higher BMI, as per Asia Pacific cut-off criteria, did not significantly impact the haemolysis of blood bags. Stored RBCs with SAGM, especially of donors having BMI > 23, had a protective effect against haemolysis in blood bags. The percentage of haemolysis was positively correlated with the haematocrit of stored RBC in bags.

包装红细胞(PRBC)的质量受到多种因素的影响,如收集和处理方法、储存条件、使用的袋材料类型、抗凝性能和献血者特征。研究表明,储存红细胞袋中的溶血与男性、年龄较大、血红蛋白计数高和体重指数(BMI)增加有关。该研究的主要目的是调查捐献者的高BMI(按照亚太标准)是否与储存的红细胞溶血率升高有关。此外,该研究旨在检查血袋中添加的不同类型的防腐剂在储存过程中对红细胞溶血的保护作用。方法:对100例不同BMI的献血者的红细胞在储存0、21和最后一天(35/42天)的溶血情况进行分析。对于健康和超重的献血者,BMI的临界值为23。选择用于储存的血袋要么含有添加剂溶液(SAGM),要么不含添加剂和抗凝剂。分析了溶血百分比与供体年龄、BMI和血红蛋白等不同变量的关系。测定血袋红细胞压积与溶血的相关性。结果:本研究未发现BMI较高的血袋在储存最后一天溶血百分比有显著增加(p = 0.424)。无SAGM袋溶血率高于有添加溶液袋溶血率(p = 0.000)。袋内高红细胞压积与溶血率呈正相关(p = 0.002)。与储存在CPD-SAGM袋中的红细胞相比,BMI bbbb23组供体红细胞单位的CPDA-1袋的溶血率显著提高(p = 0.000)。结论:按照亚太地区的截止标准,BMI较高的印度人群对血袋溶血没有显著影响。储存有SAGM的红细胞,特别是BMI为bbbb23的献血者,对血袋中的溶血有保护作用。溶血百分率与袋内储存红细胞的红细胞压积呈正相关。
{"title":"The impact of Asian-Indian criteria for higher body mass index and preservative solutions on haemolysis of stored red blood cells: A prospective observational study.","authors":"Somnath Mukherjee, Stephy Varghese K, Satya Prakash, Debasish Mishra, Ansuman Sahu","doi":"10.1111/tme.13120","DOIUrl":"10.1111/tme.13120","url":null,"abstract":"<p><strong>Introduction: </strong>The quality of packed red blood cells (PRBC) is influenced by various factors such as the collection and processing method, storage conditions, type of bag materials used, anticoagulant properties, and donor characteristics. Studies have indicated that haemolysis in stored RBC bags is linked to male sex, older age, high haemoglobin count, and increased body mass index (BMI). The study's primary objective was to investigate whether a high BMI, as per Asian Pacific criteria among donors, is associated with an elevated haemolysis rate in stored RBC. Additionally, the study aimed to examine any protective effects of different types of preservatives added to blood bags against RBC haemolysis during storage.</p><p><strong>Methods: </strong>Stored RBCs from 100 blood donors with different BMI are analysed for haemolysis on 0, 21, and last day (35/42 days) of storage. A BMI cut-off of 23 was taken for healthy and overweight consideration in blood donors. The blood bags selected for storage were either with additive solution (SAGM) or without additive along with an anticoagulant. The association of the percentage of haemolysis with different variables like age, BMI, and Haemoglobin of the donor were analysed. The correlation between the haematocrit of the bag and haemolysis was determined.</p><p><strong>Results: </strong>This study did not find any significant increase in the percentage of haemolysis in blood bags with higher BMI on the last day of storage (p = 0.424). The haemolysis percentage was higher in bags without SAGM than in bags with an additive solution (p = 0.000). The high haematocrit of the bag has a significant positive correlation with the percentage of haemolysis (p = 0.002). Significantly higher haemolysis in CPDA-1 bags of donor RBC units of BMI >23 groups was observed (p = 0.000) compared to those stored in CPD-SAGM bags.</p><p><strong>Conclusion: </strong>Indian population for higher BMI, as per Asia Pacific cut-off criteria, did not significantly impact the haemolysis of blood bags. Stored RBCs with SAGM, especially of donors having BMI > 23, had a protective effect against haemolysis in blood bags. The percentage of haemolysis was positively correlated with the haematocrit of stored RBC in bags.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"144-150"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142906924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Universal new blood cell elution method with extensive phenotyping. 具有广泛表型的通用新型血细胞洗脱方法。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-04-01 Epub Date: 2025-02-09 DOI: 10.1111/tme.13126
Lorraine Caruccio, Karen Byrne, David F Stroncek

Background/objectives: No erythrocyte elution method developed is uniformly successful or allows elution/phenotyping together. We previously developed an elution method using deionised formamide. We modified it to be universal for various cell types and call it modified formamide-method (Fm-method). It also preserves cells for phenotyping after elution.

Materials and methods: Fm-method reagent contains deionised formamide, buffered high salt, EDTA, TE. Elution-reagent is removed by column centrifugation. Blood samples were used for development and validation. Results compared to commercial/common antibody elution/phenotyping methods.

Results: Fm-method eluted antibodies, complement, other proteins, and nucleic acids and works with erythrocytes, leukocytes, other cells. It worked better than commercial kits used for elution/phenotyping with no false positives/negatives. It did not denature Kell and Lewis antigens and could be repeated as needed on samples to recover more antibodies and clean cells for phenotyping. Western blotting, PAGE and FCM demonstrated eluted proteins were not degraded and cells remained intact.

Conclusion: Fm-method is excellent for elution and phenotyping and permits elution and phenotyping with one method and sample. It is useful for studies of various bound molecules and cell surface structures. It should be possible to elute various simple and complex carbohydrates as well. The Fm-method is efficient, inexpensive, scalable, uses common reagents. It should have excellent applications in various clinical, research, commercial settings.

背景/目的:没有一种红细胞洗脱方法是一致成功的,也没有一种方法可以同时进行洗脱和表型分析。我们之前开发了一种使用去离子化甲酰胺的洗脱方法。我们对其进行了修改,使其适用于各种细胞类型,并将其称为改性甲酰胺法(Fm-method)。它还保存细胞,以便洗脱后进行表型分析。材料和方法:fm法试剂含有去离子化甲酰胺、缓冲高盐、EDTA、TE。洗脱试剂通过柱离心除去。血液样本用于开发和验证。结果与商业/普通抗体洗脱/表型分析方法比较。结果:荧光显微镜法可洗脱抗体、补体、其他蛋白质和核酸,并可用于红细胞、白细胞和其他细胞。它比用于洗脱/表型的商业试剂盒更好,没有假阳性/阴性。它不会使Kell和Lewis抗原变性,并且可以根据需要在样品上重复,以恢复更多的抗体和清洁细胞以进行表型分析。Western blotting, PAGE和FCM显示洗脱的蛋白没有降解,细胞保持完整。结论:荧光显微镜法具有较好的洗脱和表型分析效果,可以用一种方法和样品进行洗脱和表型分析。它可用于研究各种结合分子和细胞表面结构。它也应该可以洗脱各种简单和复杂的碳水化合物。该方法高效、廉价、可扩展,使用常用试剂。它应该在各种临床、研究和商业环境中有很好的应用。
{"title":"Universal new blood cell elution method with extensive phenotyping.","authors":"Lorraine Caruccio, Karen Byrne, David F Stroncek","doi":"10.1111/tme.13126","DOIUrl":"10.1111/tme.13126","url":null,"abstract":"<p><strong>Background/objectives: </strong>No erythrocyte elution method developed is uniformly successful or allows elution/phenotyping together. We previously developed an elution method using deionised formamide. We modified it to be universal for various cell types and call it modified formamide-method (Fm-method). It also preserves cells for phenotyping after elution.</p><p><strong>Materials and methods: </strong>Fm-method reagent contains deionised formamide, buffered high salt, EDTA, TE. Elution-reagent is removed by column centrifugation. Blood samples were used for development and validation. Results compared to commercial/common antibody elution/phenotyping methods.</p><p><strong>Results: </strong>Fm-method eluted antibodies, complement, other proteins, and nucleic acids and works with erythrocytes, leukocytes, other cells. It worked better than commercial kits used for elution/phenotyping with no false positives/negatives. It did not denature Kell and Lewis antigens and could be repeated as needed on samples to recover more antibodies and clean cells for phenotyping. Western blotting, PAGE and FCM demonstrated eluted proteins were not degraded and cells remained intact.</p><p><strong>Conclusion: </strong>Fm-method is excellent for elution and phenotyping and permits elution and phenotyping with one method and sample. It is useful for studies of various bound molecules and cell surface structures. It should be possible to elute various simple and complex carbohydrates as well. The Fm-method is efficient, inexpensive, scalable, uses common reagents. It should have excellent applications in various clinical, research, commercial settings.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"151-167"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serological investigations on penicillin-induced antibodies in the Thai population. 泰国人群青霉素诱导抗体的血清学调查。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-01 DOI: 10.1111/tme.13117
Piyathida Khumsuk, Oytip Nathalang, Tanaporn Choychimplee, Wiradee Sasikarn, Kamphon Intharanut

Objectives: The study aimed to assess the conditions for coating RBCs with penicillin and examine the anti-penicillin reactions of random Thai patients' sera against penicillin-coated RBCs and normal sera from Thai donors testing in the presence of the drug.

Background: Penicillin-induced immunologic haemolytic anaemia (IHA) is reportedly related to possessing antipenicillin antibodies, immunoglobulin G (IgG), which has been identified in testing penicillin-coated red blood cells (RBCs). In addition, low titre penicillin antibodies, often IgM, are detected in donors by testing in the presence of a solution of the penicillin.

Materials and methods: Penicillin-coated RBCs were produced, and antipenicillin was tested against those penicillin-coated RBCs amongst random Thai patients who had strongly positive direct antiglobulin (≥3+). Additionally, sera from Thai blood donors were tested in the presence of the penicillin. These relationships were determined by comparing the numbers of penicillin-antibody positive patients with their diagnosis, sex, age and blood type.

Results: Penicillin requires a high pH to optimally adhere to RBCs that showed validated reactions with controls. Enrolment of 304 random patients, of whom 17 (5.59%) had positive antipenicillin tests using penicillin-coated RBCs. Of the 246 donor samples, 3 (1.22%) displayed positive reactivities in the presence of soluble penicillin. Furthermore, no association was discovered between the patient's characteristics and antipenicillin positivity.

Conclusions: This is the first study to develop and report on the low percentage of patients' and donors' sera without IHA. Investigating suspected cases of penicillin-induced IHA requires following our suggested method to identify clinically significant antipenicillin.

目的:本研究旨在评估青霉素包膜红细胞的条件,并检查随机泰国患者血清对青霉素包膜红细胞和泰国供者正常血清在药物存在下的抗青霉素反应。背景:据报道,青霉素诱导的免疫性溶血性贫血(IHA)与拥有抗青霉素抗体免疫球蛋白G (IgG)有关,该抗体已在检测青霉素包被红细胞(rbc)中被鉴定出来。此外,低滴度的青霉素抗体,通常是IgM抗体,通过在存在青霉素溶液的情况下检测供体。材料和方法:制备青霉素包被红细胞,随机选取直接抗球蛋白(≥3+)阳性的泰国患者进行青霉素包被红细胞的抗青霉素试验。此外,对泰国献血者的血清进行了青霉素检测。这些关系是通过比较青霉素抗体阳性患者的数量与其诊断、性别、年龄和血型来确定的。结果:青霉素需要高pH值才能最佳地粘附在红细胞上,而红细胞与对照组的反应是有效的。随机入组304例患者,其中17例(5.59%)青霉素包被红细胞抗青霉素试验阳性。在246份供体样本中,3份(1.22%)在可溶性青霉素存在下显示阳性反应。此外,没有发现患者的特征和抗青霉素阳性之间的联系。结论:这是第一个开发和报告低百分比的患者和供体血清不含IHA的研究。调查疑似青霉素诱导的IHA病例需要遵循我们建议的方法来识别临床有效的抗青霉素药物。
{"title":"Serological investigations on penicillin-induced antibodies in the Thai population.","authors":"Piyathida Khumsuk, Oytip Nathalang, Tanaporn Choychimplee, Wiradee Sasikarn, Kamphon Intharanut","doi":"10.1111/tme.13117","DOIUrl":"10.1111/tme.13117","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to assess the conditions for coating RBCs with penicillin and examine the anti-penicillin reactions of random Thai patients' sera against penicillin-coated RBCs and normal sera from Thai donors testing in the presence of the drug.</p><p><strong>Background: </strong>Penicillin-induced immunologic haemolytic anaemia (IHA) is reportedly related to possessing antipenicillin antibodies, immunoglobulin G (IgG), which has been identified in testing penicillin-coated red blood cells (RBCs). In addition, low titre penicillin antibodies, often IgM, are detected in donors by testing in the presence of a solution of the penicillin.</p><p><strong>Materials and methods: </strong>Penicillin-coated RBCs were produced, and antipenicillin was tested against those penicillin-coated RBCs amongst random Thai patients who had strongly positive direct antiglobulin (≥3+). Additionally, sera from Thai blood donors were tested in the presence of the penicillin. These relationships were determined by comparing the numbers of penicillin-antibody positive patients with their diagnosis, sex, age and blood type.</p><p><strong>Results: </strong>Penicillin requires a high pH to optimally adhere to RBCs that showed validated reactions with controls. Enrolment of 304 random patients, of whom 17 (5.59%) had positive antipenicillin tests using penicillin-coated RBCs. Of the 246 donor samples, 3 (1.22%) displayed positive reactivities in the presence of soluble penicillin. Furthermore, no association was discovered between the patient's characteristics and antipenicillin positivity.</p><p><strong>Conclusions: </strong>This is the first study to develop and report on the low percentage of patients' and donors' sera without IHA. Investigating suspected cases of penicillin-induced IHA requires following our suggested method to identify clinically significant antipenicillin.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"168-176"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142772570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alloanti-Hy in antenatal patients: A multi-case review. 同种异体抗- hy在产前患者:一个多病例回顾。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-04-01 Epub Date: 2025-01-25 DOI: 10.1111/tme.13124
S Lewis, N Kirkpatrick, A Nawrocki, L Reyland, B Jones, R Laundy, A McNeil, V Karamatic Crew, T Stutt, D Clinton, A Anbazhagan, C Harris, I Skidmore, T Bullock, M Hazell

Introduction: Introduction The Hy antigen is one of ten red cell antigens belonging to the Dombrock blood group system, with an antigen frequency of almost 100% in the majority of populations. Alloantibodies to high prevalence antigens cause difficulties with antibody identification and exclusion in serological investigations.

Case presentation: This review describes the management of four antenatal cases where the presence of alloanti-Hy had been identified. Hy-red blood cell units may be required for the transfusion of patients with alloanti-Hy, but currently, there are no published reports of alloanti-Hy causing haemolytic disease of the fetus and newborn (HDFN). A previous case report involving the care and management of antenatal patients with alloanti-Hy antibodies indicates a lack of evidence that alloanti-Hy causes clinical HDFN.

Results: All cases discussed in this review demonstrate a reduction in the strength of alloanti-Hy levels as pregnancy progressed. Signs or symptoms of HDFN were not observed with any of the pregnancies.

Conclusion: Factors such as antibody levels, antigenic expression, and varying clinical responses enhance our understanding of why alloanti-Hy has not been known to cause clinical HDFN. The cases presented here aim to improve understanding of alloanti-Hy in pregnancy and how to manage such cases.

Hy抗原是属于Dombrock血型系统的十种红细胞抗原之一,在大多数人群中抗原频率几乎为100%。针对高流行抗原的同种异体抗体在血清学调查中导致抗体鉴定和排除困难。病例介绍:这篇综述描述了四个产前病例的管理,其中同种异体抗- hy的存在已经确定。输血异体抗- hy患者可能需要使用异体红细胞单位,但目前还没有发表的异体抗- hy引起胎儿和新生儿溶血性疾病(hhdn)的报告。先前的一份病例报告涉及对携带同种异体抗- hy抗体的产前患者的护理和管理,表明缺乏证据表明同种异体抗- hy会导致临床HDFN。结果:本综述中讨论的所有病例都表明,随着妊娠的进展,同种异体抗- hy水平的强度降低。在任何妊娠中均未观察到HDFN的体征或症状。结论:抗体水平、抗原表达和不同的临床反应等因素增强了我们对为什么同种异体抗- hy尚未引起临床hdn的理解。本文介绍的病例旨在提高对妊娠期同种异体抗- hy的认识以及如何处理此类病例。
{"title":"Alloanti-Hy in antenatal patients: A multi-case review.","authors":"S Lewis, N Kirkpatrick, A Nawrocki, L Reyland, B Jones, R Laundy, A McNeil, V Karamatic Crew, T Stutt, D Clinton, A Anbazhagan, C Harris, I Skidmore, T Bullock, M Hazell","doi":"10.1111/tme.13124","DOIUrl":"10.1111/tme.13124","url":null,"abstract":"<p><strong>Introduction: </strong>Introduction The Hy antigen is one of ten red cell antigens belonging to the Dombrock blood group system, with an antigen frequency of almost 100% in the majority of populations. Alloantibodies to high prevalence antigens cause difficulties with antibody identification and exclusion in serological investigations.</p><p><strong>Case presentation: </strong>This review describes the management of four antenatal cases where the presence of alloanti-Hy had been identified. Hy-red blood cell units may be required for the transfusion of patients with alloanti-Hy, but currently, there are no published reports of alloanti-Hy causing haemolytic disease of the fetus and newborn (HDFN). A previous case report involving the care and management of antenatal patients with alloanti-Hy antibodies indicates a lack of evidence that alloanti-Hy causes clinical HDFN.</p><p><strong>Results: </strong>All cases discussed in this review demonstrate a reduction in the strength of alloanti-Hy levels as pregnancy progressed. Signs or symptoms of HDFN were not observed with any of the pregnancies.</p><p><strong>Conclusion: </strong>Factors such as antibody levels, antigenic expression, and varying clinical responses enhance our understanding of why alloanti-Hy has not been known to cause clinical HDFN. The cases presented here aim to improve understanding of alloanti-Hy in pregnancy and how to manage such cases.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"197-202"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An unusual case of reagent interference in transfusion medicine workup: Pan reactive indirect antiglobulin test caused by commercial saline solution. 输血医学工作中试剂干扰的一个不寻常病例:由商用生理盐水引起的泛反应间接抗球蛋白试验。
IF 1.5 4区 医学 Q3 HEMATOLOGY Pub Date : 2025-04-01 Epub Date: 2024-11-16 DOI: 10.1111/tme.13113
Martin Tøffner Pedersen, Helle Bach-Hansen, Kristina Fruerlund Rasmussen, Mark H Yazer, Ulrik Sprogøe

Background: At the regional transfusion service in the Region of Southern Denmark, serological investigations are primarily carried out using column agglutination techniques. This case study examines an unusual instance of reagent interference in pretransfusion testing using column agglutination at the Hospital of Southern Denmark, Aabenraa.

Case presentation: A 72-year-old male patient presented for pretransfusion testing prior to hernia surgery. He typed as O RhD negative without discrepancies, but the antibody screen showed weakly positive reactions. Routine investigations showed discrepancies, leading to further investigations.

Methods: Various serological tests were performed using in-house and commercial red test cells suspended in different suspension media and with different column agglutination cards and cassettes. Further investigations included washing of test cells, testing alternative saline solutions, varying incubation temperatures, testing without antihuman-globulin, and applying proteolytic enzymes.

Results: Reactivity was present with red cells suspended in ID-CellStab (BioRad) but not in Red Cell Diluent (Quidel-Ortho). Reactivity was abolished by using trypsin-treated cells, indicating either the presence of an antibody reacting with-or unspecific agglutination depending on-a trypsin-sensitive protein, in both cases enhanced by ID-CellStab.

Conclusion: This case highlights the importance of recognising reagent-dependent reactivity in serological testing. Adjustments to the suspension media resolved the incompatibility. Immunohematology laboratories should consider potential reagent interference when unexpected agglutination occurs.

背景:在南丹麦地区的区域输血服务中,血清学检查主要采用柱凝集技术。本病例研究探讨了丹麦南部阿本拉(Aabenraa)医院在使用柱凝集法进行输血前检测时出现的试剂干扰异常情况:一名 72 岁的男性患者在疝气手术前接受输血前检测。他的分型为 O 型 RhD 阴性,无差异,但抗体筛查显示为弱阳性反应。常规检查结果显示存在差异,因此需要进一步检查:方法:使用悬浮在不同悬浮培养基中的自制和商用红检测细胞以及不同的柱凝集卡和凝集盒进行了各种血清学检测。进一步的研究包括洗涤检测细胞、测试替代生理盐水溶液、改变孵育温度、在不使用抗人球蛋白的情况下进行测试以及使用蛋白水解酶:结果:悬浮在 ID-CellStab (BioRad)中的红细胞会发生反应,而悬浮在红细胞稀释液(Quidel-Ortho)中的红细胞不会发生反应。使用胰蛋白酶处理过的细胞可消除反应,这表明存在与胰蛋白酶敏感蛋白反应的抗体或取决于胰蛋白酶敏感蛋白的非特异性凝集,在这两种情况下,ID-CellStab 均可增强反应:本病例强调了在血清学检测中识别试剂依赖性反应的重要性。对悬浮培养基的调整解决了不相容问题。当出现意外凝集时,免疫血液学实验室应考虑潜在的试剂干扰。
{"title":"An unusual case of reagent interference in transfusion medicine workup: Pan reactive indirect antiglobulin test caused by commercial saline solution.","authors":"Martin Tøffner Pedersen, Helle Bach-Hansen, Kristina Fruerlund Rasmussen, Mark H Yazer, Ulrik Sprogøe","doi":"10.1111/tme.13113","DOIUrl":"10.1111/tme.13113","url":null,"abstract":"<p><strong>Background: </strong>At the regional transfusion service in the Region of Southern Denmark, serological investigations are primarily carried out using column agglutination techniques. This case study examines an unusual instance of reagent interference in pretransfusion testing using column agglutination at the Hospital of Southern Denmark, Aabenraa.</p><p><strong>Case presentation: </strong>A 72-year-old male patient presented for pretransfusion testing prior to hernia surgery. He typed as O RhD negative without discrepancies, but the antibody screen showed weakly positive reactions. Routine investigations showed discrepancies, leading to further investigations.</p><p><strong>Methods: </strong>Various serological tests were performed using in-house and commercial red test cells suspended in different suspension media and with different column agglutination cards and cassettes. Further investigations included washing of test cells, testing alternative saline solutions, varying incubation temperatures, testing without antihuman-globulin, and applying proteolytic enzymes.</p><p><strong>Results: </strong>Reactivity was present with red cells suspended in ID-CellStab (BioRad) but not in Red Cell Diluent (Quidel-Ortho). Reactivity was abolished by using trypsin-treated cells, indicating either the presence of an antibody reacting with-or unspecific agglutination depending on-a trypsin-sensitive protein, in both cases enhanced by ID-CellStab.</p><p><strong>Conclusion: </strong>This case highlights the importance of recognising reagent-dependent reactivity in serological testing. Adjustments to the suspension media resolved the incompatibility. Immunohematology laboratories should consider potential reagent interference when unexpected agglutination occurs.</p>","PeriodicalId":23306,"journal":{"name":"Transfusion Medicine","volume":" ","pages":"192-196"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11998997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Transfusion Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1